DISTINGUISHING A BENZODIAZEPINE AGONIST (TRIAZOLAM) FROM A NONAGONIST ANXIOLYTIC (BUSPIRONE) BY ELECTROENCEPHALOGRAPHY - KINETIC-DYNAMIC STUDIES

被引:52
作者
GREENBLATT, DJ [1 ]
HARTMATZ, JS [1 ]
GOUTHRO, TA [1 ]
LOCKE, J [1 ]
SHADER, RI [1 ]
机构
[1] TUFTS UNIV NEW ENGLAND MED CTR,DIV CLIN PHARMACOL,BOSTON,MA
关键词
D O I
10.1038/clpt.1994.106
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and objectives: Benzodiazepine agonists and azaperone derivatives are used clinically as anxiolytics but have different neuroreceptor mechanisms of action. This study evaluated clinical pharmacodynamic approaches to distinguishing these two classes of compounds. Methods: Healthy volunteers received single oral doses of placebo, the benzodiazepine agonist triazolam (0.25 mg) or the azaperone anxiolytic buspirone (20 mg), in a double-blind, three-way crossover study. Ratings of mood and sedation, performance on the digit symbol substitution test (DSST), and quantitative measures of electroencephalographic (EEG) beta activity (13 to 31.75 cycles/sec) determined by fast-Fourier transform were obtained at multiple times after dosage. Results: Triazolam significantly increased self- and observer-rated sedation, impaired DSST performance, impaired recall, and increased EEG beta activity. Pharmacodynamic changes were significantly intercorrelated; all effects were maximal 1 to 2 hours after dosage but were indistinguishable from placebo by 8 hours. Buspirone did not alter the EEG or DSST performance but did increase self-ratings of sedation and feeling ''spacey'' and impaired memory function; these effects generally were quantitatively less than with triazolam. Peak plasma triazolam concentrations preceded maximum pharmacodynamic effects; the mean plasma effect site equilibration half-life was 9.4 minutes. Kinetic-dynamic modeling procedures yielded significant relationships between hypothetical effect site triazolam concentrations and pharmacodynamic changes. Conclusions: Quantitative analysis of the EEG clearly distinguishes a typical benzodiazepine agonist from a nonagonist anxiolytic, in clinically relevant dosage, whose pharmacodynamic actions do not involve benzodiazepine receptor occupancy. EEG effects associated with triazolam are intercorrelated with other pharmacodynamic measures.
引用
收藏
页码:100 / 111
页数:12
相关论文
共 60 条
  • [1] ARENDT RM, 1983, J PHARMACOL EXP THER, V227, P95
  • [2] TRIAZOLAM CONCENTRATION-EFFECT RELATIONSHIPS IN HEALTHY-SUBJECTS
    BAKTIR, G
    FISCH, HU
    HUGUENIN, P
    BIRCHER, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (02) : 195 - 201
  • [3] BARBEE JG, 1991, J CLIN PSYCHOPHARM, V11, P351
  • [4] BARBEE JG, 1992, J NEUROPSYCH CLIN N, V4, P308
  • [5] BARRETT JE, 1986, J PHARMACOL EXP THER, V238, P1009
  • [6] BERLIN I, 1993, J CLIN PSYCHOPHARM, V13, P100
  • [7] BUSPIRONE AND DIAZEPAM - COMPARISON OF SUBJECTIVE, PSYCHOMOTOR AND BIOLOGICAL EFFECTS
    BOULENGER, JP
    SQUILLACE, K
    SIMON, P
    HERROU, M
    LEYMARIE, P
    ZARIFIAN, E
    [J]. NEUROPSYCHOBIOLOGY, 1989, 22 (02) : 83 - 89
  • [8] QUANTIFICATION OF THE EEG EFFECT OF MIDAZOLAM BY APERIODIC ANALYSIS IN VOLUNTEERS - PHARMACOKINETIC PHARMACODYNAMIC MODELING
    BREIMER, LTM
    HENNIS, PJ
    BURM, AGL
    DANHOF, M
    BOVILL, JG
    SPIERDIJK, J
    VLETTER, AA
    [J]. CLINICAL PHARMACOKINETICS, 1990, 18 (03) : 245 - 253
  • [9] BUHRER M, 1990, CLIN PHARMACOL THER, V48, P555
  • [10] BUHRER M, 1990, CLIN PHARMACOL THER, V48, P544